The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp478
GLUTEN INDUCED CYTOKINE RELEASE; NEW FINDINGS AND IMPLICATIONS
Date
May 7, 2023
Explore related products in the following collection:
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases. This session is planned as a mixed session with overviews of new concepts in cellular and cytokine manifestations of celiac disease followed by presentation of relevant abstracts.
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…